aod9604 fda approved AOD-9604-10MG AOD-9604 - Peptide for Fat

A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007

These animals were also subjected to the same environmental conditions and treatment protocols for a chronic 28-day administration study [2]

Nicotinamide-N-methyltransferase controls behavior, neurodegeneration and lifespan by regulating neuronal autophagy

Over a 28-day period, lean WT mice treated with either compound exhibited increased body weight, replicating results seen in the shorter 14-day study